Oral EPI-7386 in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Pachynski, Russell Kent
Iannotti, Nicholas
Laccetti, Andrew Leonard
Carthon, Bradley Curtis
Chi, Kim N.
Smith, Matthew Raymond
Vogelzang, Nicholas J.
Tu, Wilson
Kwan, Edmond Michael
Wyatt, Alexander William
Villaluna, Karen
Younginger, Brett
Cesano, Alessandra
机构：
[1] Washington Univ Sch Med, St Louis, MO USA
[2] Treasure Coast, Hematol Oncol Assoc, Port St Lucie, FL USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[5] Vancouver Ctr, BC Canc, Vancouver, BC, Canada
[6] Massachusetts Gen Hosp, Boston, MA USA
[7] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[8] Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada
[9] Essa Pharmaceut, South San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
177
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A PHASE 1B TRIAL OF MASOFANITEN (EPI-7386) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Andrew, Laccetti
    Nicholas, Iannotti
    Russell, Pachynski
    Bradley, Carthon
    Kim, N. Chi
    Matthew, Smith
    Fred, Saad
    Roberto, Pili
    Wilson, Tu
    Edmond, M. Kwan
    Alexander, W. Wyatt
    Karen, Villaluna
    Brett, Younginger
    Le, Moigne Ronan
    Alessandra, Cesano
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [2] Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer.
    Le Moigne, Ronan
    Pearson, Paul
    Lauriault, Veronique
    Hong, Nan Hyung
    Virsik, Peter
    Zhou, Han-Jie
    Cesano, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
    Laccetti, Andrew Leonard
    Chatta, Gurkamal S.
    Iannotti, Nicholas
    Kyriakopoulos, Christos
    Villaluna, Karen
    Le Moigne, Ronan
    Cesano, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [4] Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
    Laccetti, A. L.
    Chatta, G.
    Kyriakopoulos, C.
    Iannotti, N.
    Hotte, S. J.
    Markowski, M. C.
    Pili, R.
    Vuky, J.
    Zhang, J.
    Saad, F.
    Villaluna, K.
    Younginger, B.
    Le Moigne, R.
    Cesano, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S982 - S983
  • [5] Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.
    Bikkasani, Krishna
    Qin, Qian
    Lin, Justin
    Galsky, Matt D.
    Liaw, Bobby Chi-Hung
    Oh, William K.
    Tsao, Che-Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [7] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [8] CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.
    Chen, Gang
    Karzai, Fatima
    Madan, Ravi Amrit
    Cordes, Lisa M.
    Bilusic, Marijo
    Owens, Helen
    Hankin, Amy
    Williams, Monique
    Couvillon, Anna
    Gulley, James L.
    Dahut, William L.
    Thomas, Anish
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] THE ASSOCIATION OF BMI AND DM WITH SURVIVAL AMONG PATIENTS WITH METASTATIC OR CASTRATION-RESISTANT PROSTATE CANCER.
    Glaser, Zachary A.
    Avulova, Svetlana
    Stocks, Blair
    Penson, David F.
    Moses, Kelvin A.
    JOURNAL OF UROLOGY, 2017, 197 (04) : E769 - E769
  • [10] Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.
    Vjaters, Egils
    Fizazi, Karim
    James, Nicholas D.
    Tammela, Teuvo
    Matsubara, Nobuaki
    Priou, Frank
    Lesimple, Thierry
    Bono, Petri
    Kataja, Vesa V.
    Garcia, Jorge A.
    Protheroe, Andrew
    Aspegren, John
    Joensuu, Heikki
    Kuss, Iris
    Thiele, Silke
    Fiala-Buskies, Sabine
    Jones, Robert Hugh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345